EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
New Atlas3d
Weight-loss pill passes important safety test in clinical trial
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
verywellhealth5d
GLP-1 Drug Shortage Is Over. Why Might These Drugs Soon Be Costlier and Harder to Access?
The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...
Barclays Sticks to Their Buy Rating for Novo Nordisk (0QIU)
Barclays analyst Emily Field maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Business Insider6d
Novo Nordisk (0QIU) Receives a Hold from UBS
Begin your TipRanks Premium journey today. Novo Nordisk (0QIU) Company Description: With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of ...